Pharmacogenomics: marshalling the human genome to individualise drug therapy - Wikidata - awgldk - TriplyDB

Pharmacogenomics: marshalling the human genome to individualise drug therapy

Pharmacogenomics: marshalling the human genome to individualise drug therapy

http://www.wikidata.org/entity/Q35090217

about

Differential Gene Expression across Breed and Sex in Commercial Pigs Administered Fenbendazole and Flunixin Meglumine State of Art of Cancer Pharmacogenomics in Latin American Populations.Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach.Pharmacogenomic knowledge representation, reasoning and genome-based clinical decision support based on OWL 2 DL ontologies.Drug metabolism and pharmacogenetics: the British contribution to fields of international significance Role of pharmacogenomics in the treatment of tuberculosis: a review New pathways for alimentary mucositis.Implementing Precision Medicine: The Ethical Challenges.N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures - A pilot study.Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability Genetic polymorphism analysis of cytochrome P4502E1 (CYP2E1) in a Chinese Tibetan population.

P2860

Q27318232-ACEE82EA-1452-450D-8870-414C497A22ED Q33838298-787CD727-8C5D-486F-BAC2-0046E2E10D44 Q33849108-1E88E5F5-733E-4677-A5E7-B838B201BA52 Q35121473-1998CFBE-9A4D-4249-85F7-8642CB12541B Q36364455-F53952DF-210E-4264-9EAD-21904A1C26A4 Q36441540-79A92805-D870-48D8-9782-6C869AF4ED48 Q37405948-20E84B3B-6937-4626-9478-168EFE29E651 Q39034897-9917FACC-FC67-4B3B-B726-62D601F452A3 Q41674917-7341F6B8-4EF6-49A8-AE14-2E89C9BAB7AF Q41877081-B14BB417-10F8-41F6-A209-CEF80F615DD1 Q47643728-8D30F27C-C13B-492B-A3C6-815D652131B5

P2860

Pharmacogenomics: marshalling the human genome to individualise drug therapy

http://www.wikidata.org/entity/Q35090217

description

2003 nî lūn-bûn

@nan

2003 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Pharmacogenomics: marshalling the human genome to individualise drug therapy

@ast

Pharmacogenomics: marshalling the human genome to individualise drug therapy

@en

type

label

Pharmacogenomics: marshalling the human genome to individualise drug therapy

@ast

Pharmacogenomics: marshalling the human genome to individualise drug therapy

@en

prefLabel

Pharmacogenomics: marshalling the human genome to individualise drug therapy

@ast

Pharmacogenomics: marshalling the human genome to individualise drug therapy

@en

P1433

Q35090217-B1B6C817-2CD5-486B-B5DB-3253624B7E31

P1476

Q35090217-E7E6978C-C880-4DA8-B826-68D6FEDC69AF

P2093

Q35090217-DB102683-2704-4268-B93A-D08218DEC021

P2860

Q35090217-03DBCFF9-F9FF-467C-BB02-5CF454FC5548

Q35090217-04DEDBA5-6EE6-4476-BDDF-85DE3FB31CB3

Q35090217-07D7AC31-1152-4A48-BC6B-62643C307CAB

Q35090217-1064622E-7442-43B3-87A6-0C09EB2FAE7F

Q35090217-115B3786-48CC-44CE-B28F-B064F2570D56

Q35090217-1C5A1ADD-DA63-42F8-8452-ED1DFE5258EA

Q35090217-1DB25C14-AADA-473F-94B0-EA3A70014D9C

Q35090217-1F70E0B4-9565-42DE-94E0-81506481DEB2

Q35090217-1F7D608D-F7C5-40FF-85CA-9A14149EF6DC

Q35090217-2098B8E9-0D57-4D30-946C-424DD82140CC

P304

Q35090217-636DEF4B-CE8C-4BE9-A310-C53A01858224

P31

Q35090217-FA3D45F7-26EC-42D2-9E74-040639759D23

P356

Q35090217-F76B54E4-43CD-4514-A230-879FFAD93719

P407

Q35090217-0079D02C-B2E8-4047-9747-A5E1EA5C1CBE

P478

Q35090217-05127996-1060-48C8-833A-9122A0E21226

P577

Q35090217-83E69EF7-EA38-44F0-9855-99B256314578

P698

Q35090217-08306416-B86C-4CA6-9A7C-1B8B1640E928

P921

Q35090217-3ED239EC-5148-4424-A91E-2946536DAD15

P932

Q35090217-997D91B6-CB76-422B-B477-695D0C25AC46

P356

GUT.52.SUPPL_2.II10

P1433

P1476

Pharmacogenomics: marshalling the human genome to individualise drug therapy

@en

P2093

W E Evans

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans

The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics

Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity

A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians

Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity

Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations

A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms

P304

ii10-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.52.SUPPL_2.II10

http://www.w3.org/2001/XMLSchema#string

P407

P478

52 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2003-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12651877

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

P932

1867751

http://www.w3.org/2001/XMLSchema#string